Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations.
<h4>Background</h4>Personalized medicine requires accurate molecular profiling for targeted therapy decisions. Insufficient tissue yield or tumor heterogeneity frequently limits the correct tissue biomarker determination. As a noninvasive complement to traditional tissue biopsies, liquid...
Main Authors: | Jason C Poole, Shan-Fu Wu, Timothy T Lu, Cecile Rose T Vibat, Anh Pham, Errin Samuelsz, Manisha Patel, Jeffrey Chen, Tony Daher, Veena M Singh, Lyle J Arnold |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0223112 |
Similar Items
-
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01) -
EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
by: Valérie Costes, et al.
Published: (2013-03-01) -
Pathological Factors Affecting DNA Quality in BRAF, EGFR, and KRAS Gene Molecular Tests
by: Hyon-Goo Yun, et al.
Published: (2020-12-01) -
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01) -
Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
by: Chengjuan Zhang, et al.
Published: (2017-01-01)